HilleVax (NASDAQ:HLVX – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 16.96% from the stock’s previous close.
Other research analysts also recently issued research reports about the company. Stifel Nicolaus downgraded HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the stock from $34.00 to $3.00 in a report on Tuesday, July 9th. Guggenheim downgraded shares of HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Leerink Partnrs lowered shares of HilleVax from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 9th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 price target (down from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Finally, SVB Leerink downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $28.00 to $2.00 in a research report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.20.
View Our Latest Analysis on HLVX
HilleVax Stock Up 7.5 %
HilleVax (NASDAQ:HLVX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). On average, equities research analysts predict that HilleVax will post -2.58 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the transaction, the director now directly owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 71.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. EntryPoint Capital LLC acquired a new stake in HilleVax in the first quarter worth about $80,000. SG Americas Securities LLC acquired a new stake in shares of HilleVax in the 4th quarter worth approximately $139,000. Tidal Investments LLC bought a new position in shares of HilleVax in the first quarter valued at approximately $207,000. abrdn plc acquired a new position in shares of HilleVax during the fourth quarter valued at approximately $433,000. Finally, Swiss National Bank raised its holdings in HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 86.42% of the company’s stock.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Featured Stories
- Five stocks we like better than HilleVax
- 5 discounted opportunities for dividend growth investors
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Insider Trades May Not Tell You What You Think
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Utilities Stocks Explained – How and Why to Invest in Utilities
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.